IL6 and COVID-19: Kang et al. reported that IL-6 is positively correlated with plasminogen activator inhibitor-1 (PAI-1) and, through the trans-signaling pathway, can induce endothelial damage and coagulopathy in patients with COVID-19–related cytokine release syndrome (CRS) (Kang et al., 2020).